Home › All Companies › COLL › Annual Report

COLLEGIUM PHARMACEUTICAL, INC (COLL) — Annual Report

AI-Powered SEC Filing Analysis

← All COLL filings
Latest Annual Report Filed: 2026-02-26

Key Insights

  • The company reported a significant increase in revenue for fiscal year 2025, indicating strong growth in their core business.
  • Collegium Pharmaceutical faced several legal challenges during the year, including patent disputes and stockholder lawsuits, which could pose risks to their future operations.
  • The company made a strategic acquisition of Ironshore, which could expand their product portfolio and market presence, but also introduces integration and execution risks.
Sentiment: Neutral Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for COLLEGIUM PHARMACEUTICAL, INC

Current Report Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.